Boardroom Alpha
Boardroom Alpha
CLRO · Current Report (Form 8-K) · Filed January 14, 2026

Clearone Inc — Current Report (Form 8-K)

Form
8-K
Filed
January 14, 2026
Period
Jan 13, 2026
Ticker
CLRO
Accession
0001753926-26-000105
Boardroom Alpha · Filing insights

ClearOne Spain settled wrongful termination claims with eight former employees for €392,809.80; all claims were dismissed.

Settlement agreement
About Clearone Inc
Market cap
$9M
1Y TSR
−44.0%
3Y TSR
−31.0%
Board grade
C-
Sector
Technology
CEO
Derek Graham
Last annual meeting: Dec 29, 2025 · View full Clearone Inc profile →
clro-20260113.htm



 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 13, 2026 (January 5, 2026)

 

ClearOne, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33660

 

87-0398877

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

5225 Wiley Post Way, Suite 500, Salt Lake City, Utah

 

84116

(Address of principal executive offices)

 

(Zip Code)

 

+1 (801) 975-7200

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 


Securities Registered Pursuant to Section 12(b) of the Act:  

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001

CLRO

The NASDAQ Capital Market





Item 1.01              Entry into a Material Definitive Agreement.

 

As previously disclosed by ClearOne, Inc., a Delaware corporation (the “Company”), in its quarterly report on Form 10-Q for the quarter ended September 30, 2025, eight former employees of ClearOne Spain, SL (“ClearOne Spain”), the Company’s wholly-owned subsidiary in Spain, filed a claim with the High Court of Justice of Aragon Spain against the Company and ClearOne Spain claiming wrongful termination and seeking unspecified statutory compensation as damages (the “Spanish Proceeding”) in connection with the Company’s reduction in force that it initiated on June 20, 2025.

 

On January 5, 2026, ClearOne Spain entered into a Settlement Agreement and Waiver of Claims with the eight former employees (the “Settlement Agreement”).   Under the terms of the Settlement Agreement, all eight former employees of ClearOne Spain agreed to dismiss and terminate all of their claims under the Spanish Proceeding in exchange for an aggregate cash payment from ClearOne Spain of  €392,809.80.

 

The foregoing summary of the Settlement Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the Settlement Agreement in the form filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 9.01              Financial Statements and Exhibits

(d)  Exhibits 

Exhibit Number

 

Exhibit Title

10.1

 

Settlement Agreement and Waiver of Claims.

104.1

 

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.




SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CLEARONE, INC.

 

 

 

Date: January 13, 2026

By:

/s/ Simon Brewer

 

 

Simon Brewer

 

 

Chief Financial Officer

 

From this filing to the watchlist

Catch material events the day they file.

Boardroom Alpha's monitors flag CEO/CFO transitions, restatements, going-concern risk, auditor changes, and 8-K events the day they hit EDGAR — across 6,000+ U.S. public companies. Daily digest by watchlist, API-accessible.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Clearone Inc (CLRO)

Reference

Frequently asked questions

When did Clearone Inc file this 8-K?
Clearone Inc (CLRO) filed this Current Report (Form 8-K) with the SEC on January 14, 2026. The accession number assigned by EDGAR is 0001753926-26-000105.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
ClearOne Spain settled wrongful termination claims with eight former employees for €392,809.80; all claims were dismissed. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What events did Boardroom Alpha flag in this filing?
BA's event-extraction layer identified this signal in the filing text: "Settlement agreement". It appears above the filing body as a labeled pill.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Clearone Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Clearone Inc has filed under CIK 840715, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer